AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 AUG 9 - (NewsRx Network) -- A major new study supports the use of testing for human papillomavirus (HPV) using Digene's Hybrid [Capture.sup.R] 2 HPV DNA Test in cervical cancer screening in low-resource settings.
The study, published in the July 2, 2001, issue of the Journal of the American Medical Association, is the first major evaluation of its kind to examine the cost effectiveness of different cervical cancer screening options in low-resource settings. The paper concluded that HPV testing is more effective and less costly than the traditional Pap smear.
The study included a cost-effectiveness analysis using a mathematical model and a hypothetical cohort of previously unscreened 35-year-old black women in sub-Saharan Africa. Screening tests evaluated included the HPV test, the traditional Pap smear, and direct visual inspection (DVI). The findings showed that a single screening with HPV testing using Digene's Hybrid Capture 2 HPV DNA Test reduced the risk of cancer incidence by 27%, compared with 19% for the traditional Pap smear. At the same time, HPV testing cost U.S. $39 per year of life saved, versus U.S. $81 per year of life saved using conventional Pap smear screening.
The study's analysis team was headed by Sue J. Goldie, MD, MPH, assistant professor of health policy at the Harvard School of Public Health, Cambridge, Massachusetts, and Thomas C. Wright, MD, director of gynecologic pathology and associate professor of ...
Source: HighBeam Research, Human Papillomavirus Test Is Cost Effective In Developing Countries.